(NASDAQ: ZVRA) Zevra Therapeutics's forecast annual revenue growth rate of 72.28% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.85%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Zevra Therapeutics's revenue in 2025 is $40,588,000.On average, 3 Wall Street analysts forecast ZVRA's revenue for 2025 to be $7,831,929,019, with the lowest ZVRA revenue forecast at $5,139,886,254, and the highest ZVRA revenue forecast at $13,210,601,266. On average, 3 Wall Street analysts forecast ZVRA's revenue for 2026 to be $8,171,872,347, with the lowest ZVRA revenue forecast at $7,091,949,438, and the highest ZVRA revenue forecast at $9,339,282,683.
In 2027, ZVRA is forecast to generate $12,200,121,500 in revenue, with the lowest revenue forecast at $10,806,884,247 and the highest revenue forecast at $13,593,358,753.